The Antiaggregation Monitoring (TAM) Registry (TAM)
Recruitment status was: Recruiting
|Aspirin Causing Adverse Effects in Therapeutic Use||Other: Measurement of platelet anti-aggregation|
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Acetylsalicylic Acid in Outpatient Practice - Results From The Antiaggregation Monitoring (TAM) Registry|
- Whole blood impedance platelet aggregometry to assess acetylsalicylic acid resistance rates [ Time Frame: 6 months ]
|Study Start Date:||November 2010|
|Estimated Study Completion Date:||April 2011|
|Estimated Primary Completion Date:||April 2011 (Final data collection date for primary outcome measure)|
All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic.
Other: Measurement of platelet anti-aggregation
Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
Acetylsalicylic acid (ASA) resistance (R) is best defined as an ineffective inhibition of the platelet cyclooxygenase (COX)-1 pathway, and has been reported in 1 to 61 % of patients treated with ASA. Impaired response to ASA has been associated with an increased risk of ischemic events in patients with known coronary artery disease. We sought to investigate the incidence of ASA-R in clinical practice.
All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic were systematically included in the registry. All patients were on acetylsalicylic acid for CAD for at least 1 month. Patients were informed of ASA testing at start of consultation in the outpatient clinic. Eligible patients provided written informed consent. Peripheral venous blood samples were analyzed using the whole blood impedance platelet aggregometry Multiplate analyzer. The Multiplate analyzer device allows to measure platelet aggregation by the attachment of platelets to two silver coated copper electrodes leading to a rise of electrical resistance in the sample. The measurements are expressed as arbitrary aggregation units (AU) and the manufacturers defined cutoffs were used: normal values were 76-136 AU, partial antiaggregation was defined as ASA values between 31 and 75 AU and complete antiaggregation was defined as ASA values < 31 AU.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01329224
|Contact: Stéphane Cook, Prof.||0041264268140||CookS@h-fr.ch|
|Contact: Markus Oberhaensli, MDemail@example.com|
|Service de Cardiologie, Hôpital Cantonal Fribourg||Recruiting|
|Fribourg, FR, Switzerland, 1708|
|Principal Investigator: Stéphane Cook, MD|
|Principal Investigator:||Stéphane Cook, Prof||Fribourg University|